Summary report of the SF e-meeting, 17 September 2013
This document is the summary report of the Stakeholder Forum e-meeting, 17 September, 2013. It presents key discussion and actions points decided at this meeting. Agenda A. General information and updates Overview of action points (last e-meeting) and their status (written status overview in the background documents) JA2 WP updates (including JA2 SAG activities update) EUnetHTA Expert meetings […]
EUnetHTA Joint Action 2 3-year Work plan (2013)
The EUnetHTA Joint Action 2 3-Year Work Plan lays out details and timelines of the activities planned in each of the eight Work Packages of EUnetHTA JA2 and guides the work of EUnetHTA throughout 2012-2015. The EUnetHTA Executive Committee monitors the implementation of the Work Plan and discusses if any prospective amendments need to be […]
WP5 Strand B – Procedure Manual V3
This document describes processes planned for conducting pilot rapid assessments for other technologies such as medical devices, surgical interventions or diagnostics. Since the Procedure Manual is a living document, further changes can be expected due to experiences gathered throughout JA2. Procedure Manual V3.pdf
EUnetHTA’s joint response to the public consultation on PAES_Amendments from IQWiG to HAS comments
Amendments_IQWiG_To_HAS_PAES joint response.pdf
Prognostic tests for breast cancer recurrence (PTBCR)
The three tests assessed in this core health technology assessment (HTA)— uPA/PAI-1 (FEMTELLE®, American Diagnostica) based on immunostaining techniques and MammaPrint® (Agendia) and Oncotype DX® (Genomic Health), based on gene expression profiling—measure multiple markers within the tumour that may indicate how the tumour is likely to develop. Agenas, Italy and SNHTA, Switzerland are the editors […]
WELCOME to the new EUnetHTA website!
EUnetHTA is delighted to welcome you to our new website with a brand new structure and design marking the transition from EUnetHTA Joint Action 1 to EUnetHTA Joint Action 2. On this website you have many possibilities of staying informed on the EUnetHTA history, activities and important news. By clicking on “about us” you can […]
The EVIDENT Database is now launched
EUnetHTA is pleased to announce the release of the Evidence Database on New Technologies (EVIDENT) produced within Work Package 7 as its third Joint Action 1 deliverable. Access to the database is now available to all EUnetHTA Partners and Associates via the following link: https://evident.has-sante.fr/has/login.xhtml. The EVIDENT Database enables sharing early information on evidence gaps identified […]
The criteria to select and prioritise health technologies for additional evidence generation is now published
EUnetHTA Work Package 7 is pleased to present its 2nd deliverable for Joint Action 1: The criteria to select and prioritise health technologies for additional evidence generation. Selection/prioritization criteria are intended to help HTA doers, funders and other stakeholders select, among new technologies, the ones for which complementary studies are really worth performing. The document […]
EUnetHTA Strategy 2012 and beyond
The EUnetHTA Strategy 2012 and beyond is now published The EUnetHTA Plenary Assembly has endorsed the EUnetHTA strategy laying down the objectives and priorities of its activities during the next few years. The more focused vision, mission and values were specifically agreed and approved by the EUnetHTA Partners. The strategy takes into account current efforts of the Members States […]
EUnetHTA Joint Action 2 starts on October 1, 2012
The EUnetHTA Joint Action 2 Grant Agreement has been signed by the EU Executive Agency for Health and Consumers and the Coordinator (Danish Health and Medicines Authority) on behalf of 37 partners in 26 EU Member States, Croatia and Norway to start its activities on October 1, 2012. For the next 3 years EUnetHTA will […]
